Yellow fever as well as larvae-eating fish and copepods, which reduce the number of larvae. For many years, copepods of the genus "Mesocyclops" have been used in Vietnam for preventing dengue fever. It eradicated the mosquito vector in several areas. Similar efforts may be effective against yellow fever. Pyriproxyfen is recommended as a chemical larvicide, mainly because it is safe for humans and effective even in small doses. The second strategy is to reduce populations of the adult yellow fever mosquito. Lethal ovitraps can reduce "Aedes" populations, but with a decreased amount of pesticide because it targets the mosquitoes directly. Curtains and
Yellow fever vaccine group established in 2000 when a global shortage of yellow fever vaccine had developed because of the long lead time to manufacture the vaccine. As of 2013, there were four WHO-qualified manufacturers: Bio-Manguinhos in Brazil (with the Oswaldo Cruz Foundation), Institute Pasteur in Dakar, Senegal, the Federal State Unitary Enterprise of Chumakov Institute in Russia, and Sanofi Pasteur, the French pharmaceutical company. Two other manufacturers supply domestic markets: Wuhan Institute of Biological Products in China and Sanofi Pasteur in the United States. Seth Berkley, the chief executive of Gavi, has warned about the worldwide threat of yellow fever because of